Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 3 Next >
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
From MaaT Pharma
Via Business Wire
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
From MaaT Pharma
Via Business Wire
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
From MaaT Pharma
Via Business Wire
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
From MaaT Pharma
Via Business Wire
MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
From MaaT Pharma
Via Business Wire
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
From MaaT Pharma
Via Business Wire
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
From MaaT Pharma
Via Business Wire
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
From MaaT Pharma
Via Business Wire
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation
From MaaT Pharma
Via Business Wire
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
From MaaT Pharma
Via Business Wire
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces New Appointments to the Board and Executive Team
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
From MaaT Pharma
Via Business Wire
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.